Editorial: Nontuberculous mycobacterial pulmonary disease: immunopathogenesis and immunological risk factors.
作者信息
Chan Edward D, Schmitz Veronica
机构信息
Department of Academic Affairs, National Jewish Health, Denver, CO, United States.
Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
出版信息
Front Immunol. 2025 Mar 21;16:1582489. doi: 10.3389/fimmu.2025.1582489. eCollection 2025.
Abstract
摘要
相似文献
1
Editorial: Nontuberculous mycobacterial pulmonary disease: immunopathogenesis and immunological risk factors.社论：非结核分枝杆菌肺病：免疫发病机制及免疫危险因素
Front Immunol. 2025 Mar 21;16:1582489. doi: 10.3389/fimmu.2025.1582489. eCollection 2025.
2
Nationwide Increasing Incidence of Nontuberculous Mycobacterial Diseases Among Adults in Denmark: Eighteen Years of Follow-Up.丹麦成年人中非结核分枝杆菌病发病率呈全国性上升趋势：十八年随访研究。
Chest. 2024 Aug;166(2):271-280. doi: 10.1016/j.chest.2024.03.023. Epub 2024 Mar 16.
3
Host immune response against environmental nontuberculous mycobacteria and the risk populations of nontuberculous mycobacterial lung disease.宿主对环境分枝杆菌的免疫反应与非结核分枝杆菌肺病的高危人群。
J Formos Med Assoc. 2020 Jun;119 Suppl 1:S13-S22. doi: 10.1016/j.jfma.2020.05.001. Epub 2020 May 22.
4
Coinfection With Multiple Nontuberculous Mycobacteria as a Possible Exacerbating Factor in Pulmonary Nontuberculous Mycobacteriosis: Clone Library Analysis Using the 16S Ribosomal RNA Gene.多重非结核分枝杆菌合并感染作为肺部非结核分枝杆菌病可能的加重因素：使用16S核糖体RNA基因的克隆文库分析
Chest. 2020 Dec;158(6):2304-2313. doi: 10.1016/j.chest.2020.06.027. Epub 2020 Jun 27.
5
Pulmonary nontuberculous mycobacterial infections among women with cystic fibrosis and non-cystic fibrosis bronchiectasis.患有囊性纤维化和非囊性纤维化支气管扩张症的女性中的肺部非结核分枝杆菌感染。
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251323181. doi: 10.1177/17534666251323181. Epub 2025 Mar 12.
6
Pathophysiology of pulmonary nontuberculous mycobacterial (NTM) disease.肺部非结核分枝杆菌（NTM）病的病理生理学
Respir Investig. 2023 Mar;61(2):135-148. doi: 10.1016/j.resinv.2022.12.002. Epub 2023 Jan 12.
7
Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance study.非结核分枝杆菌肺病及相关危险因素在中国：一项前瞻性监测研究。
J Infect. 2021 Jul;83(1):46-53. doi: 10.1016/j.jinf.2021.05.019. Epub 2021 May 25.
8
Highlight on advances in nontuberculous mycobacterial disease in North America.北美非结核分枝杆菌病进展概述。
Biomed Res Int. 2014;2014:919474. doi: 10.1155/2014/919474. Epub 2014 Sep 11.
9
Treatment outcomes of nontuberculous mycobacterial pulmonary disease in lung transplant recipients.肺移植受者中非结核分枝杆菌肺病的治疗结果。
Transpl Infect Dis. 2021 Aug;23(4):e13679. doi: 10.1111/tid.13679. Epub 2021 Jul 12.
10
Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012.2007年至2012年俄勒冈州非结核分枝杆菌肺病的人群发病率
Ann Am Thorac Soc. 2015 May;12(5):642-7. doi: 10.1513/AnnalsATS.201412-559OC.
本文引用的文献
1
The controversy of immune checkpoint inhibition and risk of mycobacterial infections: the need for further studies and continued discussions on this puzzling issue.免疫检查点抑制与分枝杆菌感染风险的争议：对这一棘手问题进行进一步研究并持续讨论的必要性。
J Thorac Dis. 2024 Aug 31;16(8):5487-5489. doi: 10.21037/jtd-24-1005. Epub 2024 Aug 28.
2
Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments.分枝杆菌生物膜：机制、临床问题与治疗。
Int J Mol Sci. 2024 Jul 16;25(14):7771. doi: 10.3390/ijms25147771.
3
Discovery of 2-phenylquinazolines as potent Mycobacterium avium efflux pump inhibitors able to synergize with clarithromycin against clinical isolate.发现 2-苯基喹唑啉类化合物作为有效的分枝杆菌外排泵抑制剂，能够与克拉霉素协同作用对抗临床分离株。
Arch Pharm (Weinheim). 2024 Oct;357(10):e2400296. doi: 10.1002/ardp.202400296. Epub 2024 Jun 26.
4
Protein-energy restriction-induced lipid metabolism disruption causes stable-to-progressive disease shift in Mycobacterium avium-infected female mice.蛋白质能量限制诱导的脂代谢紊乱导致感染鸟分枝杆菌的雌性小鼠疾病从稳定期向进展期转变。
EBioMedicine. 2024 Jul;105:105198. doi: 10.1016/j.ebiom.2024.105198. Epub 2024 Jun 17.
5
Mycobacterial biofilms: Understanding the genetic factors playing significant role in pathogenesis, resistance and diagnosis.分枝杆菌生物膜：了解在发病机制、耐药性和诊断中起重要作用的遗传因素。
Life Sci. 2024 Aug 15;351:122778. doi: 10.1016/j.lfs.2024.122778. Epub 2024 Jun 13.
6
A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?关于使用免疫检查点抑制剂引发分枝杆菌感染风险争议的叙述性综述：金发姑娘知道答案吗？
J Thorac Dis. 2024 Feb 29;16(2):1601-1624. doi: 10.21037/jtd-23-1395. Epub 2024 Feb 27.
7
Biofilm Formation in Mycobacterial Genus; Mechanism of Biofilm Formation and Anti-Mycobacterial Biofilm Agents.分枝杆菌属中的生物膜形成；生物膜形成机制及抗分枝杆菌生物膜药物
Curr Pharm Biotechnol. 2024 Mar 11. doi: 10.2174/0113892010277107240227054933.
8
Microbial Primer: An introduction to biofilms - what they are, why they form and their impact on built and natural environments.微生物入门：生物膜简介——生物膜是什么、为什么会形成生物膜以及它们对建筑和自然环境的影响。
Microbiology (Reading). 2023 Aug;169(8). doi: 10.1099/mic.0.001338.
9
PD-1 Inhibitor for Disseminated Infection in a Person With HIV.用于治疗HIV感染者播散性感染的PD-1抑制剂
Open Forum Infect Dis. 2022 Dec 28;10(1):ofac700. doi: 10.1093/ofid/ofac700. eCollection 2023 Jan.
10
Apoptosis Inhibitor of Macrophages Contributes to the Chronicity of Mycobacterium avium Infection by Promoting Foamy Macrophage Formation.巨噬细胞凋亡抑制剂通过促进泡沫巨噬细胞形成，导致鸟分枝杆菌感染的慢性化。
J Immunol. 2023 Feb 15;210(4):431-441. doi: 10.4049/jimmunol.2200306.
Zotero 插件